SEC 13F Intelligence

Managers / Q3 2024 · view latest →

Valence8 US LP

CIK 0001943819 · ONE BROADWAY, 14TH FLOOR, CAMBRIDGE, MA, 02142 · 617-233-0428

Reported Value
$241M
Q3 2024
Positions
62
Filings on Record
14
2019–present window
Filed
Nov 12, 2024
original filing

Summary

Valence8 US LP reported $241M in U.S.-listed holdings across 62 positions for Q3 2024.

The portfolio is heavily concentrated: QUAL alone accounts for 55.5% of reported value.

Compared with Q2 2024, the fund opened 47 new positions and exited 0.

Portfolio Metrics

Turnover
0.0%
vs prior filed quarter
Top-10 Concentration
+92.6%
share of reported value
Largest Position
+55.5%
Ishares Tr

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $132MQ4 ’22Q1 ’23: $170MQ2 ’23: $152MQ2 ’23Q3 ’23: $158MQ4 ’23: $171MQ4 ’23Q1 ’24: $192MQ2 ’24: $192MQ2 ’24Q3 ’24: $241MQ4 ’24: $208MQ4 ’24Q1 ’25: $213MQ2 ’25: $238MQ2 ’25Q3 ’25: $292MQ4 ’25: $337MQ4 ’25Q1 ’26: $286Mfilingsflow.com

Portfolio Composition

By security type
ETP: 91.0%Common Stock: 5.8%ADR: 2.5%Other: 0.7%
  • ETP · 91.0% · $219M
  • Common Stock · 5.8% · $14M
  • ADR · 2.5% · $6M
  • Other · 0.7% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
AZNNASTRAZENECA PLCNEW+64.0K64.0K+$5M$5M
AMGNAMGEN INCNEW+4.0K4.0K+$1M$1M
SOLENO THERAPEUTICS INCNEW+22.2K22.2K+$1M$1M
INSMINSMED INCNEW+14.5K14.5K+$1M$1M
JAZZJAZZ PHARMACEUTICALS PLCNEW+9.0K9.0K+$999,236$999,236
BMYBRISTOL-MYERS SQUIBB CONEW+17.8K17.8K+$920,196$920,196
ASCENDIS PHARMA A/SNEW+4.6K4.6K+$684,586$684,586
RAREULTRAGENYX PHARMACEUTICAL INNEW+11.1K11.1K+$618,883$618,883

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2024

36 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1QUALISHARES TRMSCI USA QLT FCT · MSCI INTL QUALTY · EAFE VALUE ETF · MSCI UK ETF NEW55.53%$134M1.97M
2QQQINVESCO QQQ TRhistory →UNIT SER 117.84%$43M88.1K
3XLPSELECT SECTOR SPDR TRSBI CONS STPLS · SBI INT-UTILS7.43%$18M217.2K
4VTVVANGUARD INDEX FDShistory →VALUE ETF7.00%$17M96.6K
5EWJISHARES INChistory →MSCI JPN ETF NEW3.22%$8M108.6K
6JAZZJAZZ PHARMACEUTICALS PLCSHS USD0.41%$999,2369.0K
7BMYBRISTOL-MYERS SQUIBB COCOM0.38%$920,19617.8K
8ASCENDIS PHARMA A/SSPONSORED ADR0.28%$684,5864.6K
9INSMINSMED INCCOM PAR $.010.24%$574,1457.9K
10INDIVIOR PLCORD0.23%$564,18657.3K
11LLYELI LILLY & COCOM0.23%$560,800633
12ARGXARGENX SESPONSORED ADR0.21%$516,602953
13SOLENO THERAPEUTICS INCCOM0.20%$490,0569.7K
14KROSKEROS THERAPEUTICS INCCOM0.19%$466,0128.0K
15NUVLNUVALENT INCCOM0.17%$420,9654.1K
16JANXJANUX THERAPEUTICS INCCOM0.15%$356,9447.9K
17CRNXCRINETICS PHARMACEUTICALS INCOM0.14%$341,5526.7K
18TYRATYRA BIOSCIENCES INCCOM0.13%$310,05013.2K
19APGEAPOGEE THERAPEUTICS INCCOM0.13%$307,7985.2K
20PCVXVAXCYTE INCCOM0.12%$282,0182.5K
21NTLAINTELLIA THERAPEUTICS INCCOM0.11%$267,56113.0K
22VIRVIR BIOTECHNOLOGY INCCOM0.10%$252,03933.6K
23BLUEPRINT MEDICINES CORPCOM0.10%$242,1652.6K
24RAREULTRAGENYX PHARMACEUTICAL INCOM0.10%$235,5884.2K
25ENTAENANTA PHARMACEUTICALS INCCOM0.09%$206,56819.9K
26RLAYRELAY THERAPEUTICS INCCOM0.08%$185,49626.2K
27ZVRAZEVRA THERAPEUTICS INCCOM NEW0.06%$149,87621.6K
28ERASERASCA INCCOM0.05%$128,10046.9K
29SLDBSOLID BIOSCIENCES INCCOM NEW0.05%$109,62415.7K
30VTGNVISTAGEN THERAPEUTICS INCCOM0.04%$103,47234.4K
31ZURA BIO LTDCLASS A ORD SHS0.03%$71,03017.5K
32ALECALECTOR INCCOM0.03%$68,53914.7K
33CLYMELIEM THERAPEUTICS INCCOM0.03%$61,30912.0K
34CYPHLEAP THERAPEUTICS INCCOM NEW0.02%$47,57318.5K
35NEKTAR THERAPEUTICSCOM0.01%$33,93926.1K
36KEZAR LIFE SCIENCES INCCOM0.01%$16,34221.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$286M14May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$337M15Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$292M14Nov 7, 202513F-HRchanges · EDGAR ↗
Q2 2025$238M12Aug 7, 202513F-HRchanges · EDGAR ↗
Q1 2025$213M10May 12, 202513F-HRchanges · EDGAR ↗
Q4 2024$208M10Feb 12, 202513F-HRchanges · EDGAR ↗
Q3 2024$241M62Nov 12, 202413F-HRchanges · EDGAR ↗
Q2 2024$192M9Aug 6, 202413F-HRchanges · EDGAR ↗
Q1 2024$192M9May 6, 202413F-HRchanges · EDGAR ↗
Q4 2023$171M9Feb 1, 202413F-HRchanges · EDGAR ↗
Q3 2023$158M13Nov 9, 202313F-HRchanges · EDGAR ↗
Q2 2023$152M13Aug 1, 202313F-HRchanges · EDGAR ↗
Q1 2023$170M14May 9, 202313F-HRchanges · EDGAR ↗
Q4 2022$132M12Jan 31, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.